OverviewSuggest Edit

Avenue Therapeutics, a Fortress Biotech Company, is a specialty pharmaceutical company that acquires/in-licenses, develops and commercializes products principally for use in the acute/hospital setting. The Company's initial product candidate is an intravenous formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain. Avenue Therapeutics plans to seek additional products to develop in the acute/hospital setting in addition to IV Tramadol.

TypePublic
Founded2015
HQNew York, US
Websiteavenuetx.com

Latest Updates

Employees (est.) (Feb 2019)2
Share Price (May 2019)$4.8 (+5%)

Key People/Management at Avenue Therapeutics

Lucy Lu

Lucy Lu

President and Chief Executive Officer
David Horin

David Horin

Interim CFO
Lindsay Rosenwald

Lindsay Rosenwald

Executive Chairman
Scott Reines

Scott Reines

Interim Chief Medical Officer
Show more

Avenue Therapeutics Office Locations

Avenue Therapeutics has an office in New York
New York, US (HQ)
2 Gansevoort St
Show all (1)

Avenue Therapeutics Financials and Metrics

Avenue Therapeutics Revenue

USD

Net income (FY, 2016)

(3.2m)

EBIT (FY, 2016)

(2.4m)

Market capitalization (21-May-2019)

79.9m

Closing stock price (21-May-2019)

4.8

Cash (31-Dec-2016)

197.0k
Avenue Therapeutics's current market capitalization is $79.9 m.
USDFY, 2015FY, 2016

General and administrative expense

842.0k997.0k

R&D expense

4.0m1.4m

Operating expense total

4.8m2.4m

EBIT

(4.8m)(2.4m)
USDFY, 2015FY, 2016

Cash

14.0k197.0k

Total Assets

14.0k197.0k

Accounts Payable

491.0k506.0k

Short-term debt

1.2m3.9m
USDFY, 2015FY, 2016

Net Income

(5.2m)(3.2m)

Accounts Payable

491.0k15.0k

Cash From Operating Activities

(895.0k)(1.6m)

Cash From Investing Activities

(3.0m)
Show all financial metrics

Avenue Therapeutics Operating Metrics

Q1, 2017

Patents Issued

622
Show all operating metrics

Avenue Therapeutics News and Updates

Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019 Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019

Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of Directors.

Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

-- Expects to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Abdominoplasty Surgery in mid-2019 -- -- Expects to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Abdominoplasty Surgery in mid-2019 --

Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage closing of the Acquisition Agreement previously announced on November 13, 2018 with InvaGen Pharmaceuticals,…

Cipla completes 1st tranche of acquisition in US-based Avenue Therapeutics

Drug major Cipla Friday said its subsidiary InvaGen Pharmaceuticals Inc has completed the first tranche of its acquisition of 33.3 per cent stake in US-based speciality business firm Avenue Therapeutics. In November last year, the company had said it intends to acquire Avenue Therapeutics, a Fortres…

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI

NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or...
Show more

Avenue Therapeutics Frequently Asked Questions

  • When was Avenue Therapeutics founded?

    Avenue Therapeutics was founded in 2015.

  • Who are Avenue Therapeutics key executives?

    Avenue Therapeutics's key executives are Lucy Lu, David Horin and Lindsay Rosenwald.

  • How many employees does Avenue Therapeutics have?

    Avenue Therapeutics has 2 employees.

  • Who are Avenue Therapeutics competitors?

    Competitors of Avenue Therapeutics include Parexel International, Fate Therapeutics and Loxo Oncology.

  • Where is Avenue Therapeutics headquarters?

    Avenue Therapeutics headquarters is located at 2 Gansevoort St, New York.

  • Where are Avenue Therapeutics offices?

    Avenue Therapeutics has an office in New York.

  • How many offices does Avenue Therapeutics have?

    Avenue Therapeutics has 1 office.